The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Pawel Petryszyn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Wroclaw Medical University, Wroclaw, Poland. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu.
Abstract (Originalsprache)
The enzyme N‐acetyltransferase 2 (NAT2) plays an important role in metabolism and detoxification of xenobiotics, including carcinogens and medications. We aimed to assess the contribution of the NAT2 polymorphism to susceptibility to inflammatory bowel disease (IBD) in the Polish population. The study involved 101 IBD patients and 100 healthy controls. The NAT2 gene mutations at positions 481T, 803G, 590A, and 857A were identified using the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) technique on peripheral blood DNA samples. Carriers of the NAT2*5 allele had a greater chance of developing Crohn's disease (CD) (OR = 1.73, 95% CI 1.06–2.83). Also, the NAT2*4/5 genotype was more prevalent in CD patients (OR = 2.77, 95% CI 1.17–6.57). When compared to the control group, the prevalence of the NAT2*4/6 genotype in the IBD patient population was significantly lower (10.9% vs. 30.0%, p < 0.01). In the Polish population, polymorphism in the NAT2 gene may potentially alter susceptibility to IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Wroclaw Medical University, Wroclaw, Poland.
- Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
- Department of Gastroenterology and Internal Medicine, University Clinical Center of the Medical University of Warsaw, Warszawa, Poland.
- Warsaw School of Economics, Warszawa, Poland.
- Calisia University, Kalisz, Poland.
ORCID-Profile: Pawel Petryszyn
Förderung
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
Zitieren
APA
Petryszyn, P., Zurakowski, G., Dudkowiak, R., Machowska, M., Gruca, A., Ekk-Cierniakowski, P., Skretkowicz, J., Poniewierka, E., Wiela-Hojenska, A., & Glowacka, K. (2025). The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70040
Vancouver
Petryszyn P, Zurakowski G, Dudkowiak R, Machowska M, Gruca A, Ekk-Cierniakowski P, et al. The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70040
BibTeX
@article{Petryszyn2025,
author = {Petryszyn, Pawel and Zurakowski, Grzegorz and Dudkowiak, Robert and Machowska, Marta and Gruca, Agnieszka and Ekk-Cierniakowski, Pawel and Skretkowicz, Jadwiga and Poniewierka, Elzbieta and Wiela-Hojenska, Anna and Glowacka, Krystyna},
title = {The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70040}
}
EUVIMED